CJC-1131. Agent for type 2 diabetes, glucagon-like peptide-1 (GLP-1) analogue

Drugs of the Future

Volumn 30, Issue 6, 2005, Pages 553-557

  Davies, S J ^a   Martin L ^a   Castaner P M ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AVE 0010; BIM 51077; CJC 1131; DAC; DILUENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; ITM 077; LIRAGLUTIDE; METFORMIN; R 1583; RECOMBINANT HORMONE; SULFONYLUREA; UNCLASSIFIED DRUG; ZP 10;

ACUTE TOXICITY; AREA UNDER THE CURVE; ARTICLE; CHRONIC TOXICITY; CLINICAL TRIAL; COVALENT BOND; DISEASE SEVERITY; DOG; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYME MECHANISM; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; STOMACH EMPTYING;

EID: 23744468231     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2005.030.06.910208     Document Type: Article

References (31)

1. Bridon, D.P., L'Archeveque, B., Ezrin, A.M., Holmes, D.L., Leblanc, A., St. Pierre, S. (ConjuChem, Inc.). Long lasting insulinotropic peptides. EP 1180121, JP 2003527312, US 6329336, WO 2000069911.
2. Léger, R., Thibaudeau, K., Robitaille, M., Quraishi, O., van Wyk, P., Bousquet-Gagnon, N., Carette, J., Castaigne, J.-P., Bridon, O.P. Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorg Med Chem Lett 2004, 14: 4395-8.
3. Prous Science Drug R&D Backgrounders: Diabetes (online publication). Updated April 28, 2005.
4. Saltiel, A.R. The molecular and physiological basis of insulin resistance: Emerging implications for metabolic and cardiovascular diseases. J Clin Invest 2000, 106: 163-4.
5. Saudek, C.D. Progress and promise of diabetes research. JAMA - J Am Med Assoc 2002, 287: 2582-4.
6. Seidell, J.C. Obesity, insulin resistance and diabetes - A worldwide epidemic. Br J Nutr 2000, 83(6, Suppl. 1): S5-8.
7. Efendic, S., Portwood, N. Overview of incretin hormones. Horm Metab Res 2004, 36: 742-6.
8. Meier, J.J., Nauck, M.A. Glucagon-like peptide 1 (GLP-1) in biology and pathology. Diabetes/Metab Res Rev 2005, 21: 91-117.
9. Vilsboell, T., Krarup, T., Deacon, C.F., Madsbad, S., Holst, J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50: 609-13.
10. Toft-Nielsen, M.-B., Damholt, M.B., Madsbad, S., Hilsted, L.M., Hughes, T.E., Michelsen, B.K., Holst, J.J. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001, 86: 3717-23.
11. Nauck, M.A., Weber, I., Bach, I., Richter, S., Orskov, C., Hoist, J.J., Schmiegel, W. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med 1998, 15: 937-45.
12. Nauck, M.A., Sauerwald, A., Ritzel, R., Holst, J.J., Schmiegel, W. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 1998, 21: 1925-31.
13. Mentlein, R., Gallwitz, B., Schmidt, W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993, 214: 829-35.
14. Baggio, L.L., Drucker, D.J. Harnessing the therapeutic potential of glucagon-like peptide-1: A critical review. Treat Endocrinol 2002, 1: 117-25.
15. Nauck, M.A., Meier, J.J. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005, 128: 135-48.
16. Holst, J.J., Orskov, C. The incretin approach for diabetes treatment: Modulation of islet hormone release by GLP-1 agonism. Diabetes 2004, 53(Suppl. 3): S197-204.
17. Benquet, C., Léger, R., Huang, X., Thibaudeau, K., Bridon, D., Castaigne, J.-P. CJC-1131 (DAC:GLP-1) binds covalently in vivo to endogenous albumin: Update on the DAC Technology. 64th Annu Meet Sci Sess Am Diabetes Assoc (June 4-8, Orlando) 2004, Abst 490-P.
18. Kim, J.-G., Baggio, L.L., Drucker, D.J. The GLP-1-DAC analogue CJC-1131 upregulates insulin gene expression and exerts a memory effect on glycemic control in db/db mice. Diabetes 2002, 51(Suppl. 2): Abst 1391-P.
19. Kim, J.-G., Baggio, L.L., Bridon, D.P., Castaigne, J.-P., Robitaille, M.F., Jetté, L., Benquet, C., Drucker, D.J. Development and characterization of a glucagon-like peptide 1-albumin conjugate. The ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003, 52: 751-9.
20. Lawrence, B., Wen, S.Y., Jette, L., Thibaudeau, K., Castaigne, J.-P. CJC-1131, the novel long acting GLP-1 analogue, delays gastric emptying and demonstrates safety and tolerability in preclinical testing. Diabetes 2002, 51(Suppl. 2): Abst 340-OR.
21. Bridon, D.P., Thibaudeau, K., L'Archeveque, B.P., Pham, K., Robitaille, M.F., Drucker, D.J., Leger, R., Castaigne, J.-P. The long-acting GLP-1 agonist CJC-1131 exhibits high potency and extended pharmacokinetics in vivo. Diabetes 2002, 51(Suppl. 2): Abst 378-P.
22. Lawrence, B., Dreyfus, J., Wen, S., Guivarc'h, P., Drucker, D., Castaigne, J.-P. CJC-1131, a long acting GLP-1 derivative, exhibits an extended pharmacokinetic profile in healthy human volunteers. Diabetes 2003, 52(Suppl. 1): Abst 534-P.
23. van Vliet, A.A., Tiessen, R.G., Kruizinga, M.H., Dreyfus, J.F., Guivarch, P.H. Pharmacokinetics and tolerability of a novel long acting glucagon-like peptide-1 analog CJC-1131. Clin Pharmacol Ther 2005, 77(2): Abst P11-17.
24. Lawrence, B., Wen, S.Y., Wilson, S., Jette, L., Drucker, D.J., Castaigne, J. Novel DAC:GLP-1 analogue, CJC-1131, exhibits prolonged efficacy, safety and tolerability following subcutaneous administration in normal and diabetic animals. Diabetologia 2002, 45(Suppl. 2): Abst 666.
25. Lawrence, B., Wen, S., Dunn, D., Iordanova, V., Castaigne, J. CJC-1131, a long-acting GLP-1 analogue, is well tolerated in rats up to 14 days. 42nd Annu Meet Soc Toxicol (March 9-13, Salt Lake City) 2003, Abst 234.
26. Wen, S., Wilson, S., Trebec, D., Pham, K., Castaigne, J., Lawrence, B. CJC-1131, a long-acting GLP-1 analogue, exhibits safety and tolerability in dogs. 42nd Annu Meet Soc Toxicol (March 9-13, Salt Lake City) 2003, Abst 230.
27. Wen, S., Chatenoud, L., Lawrence, B., Franco, P., Castaigne, J.-P., Bach, J.-F. Lack of immunogenicity of CJC-1131, a long-acting GLP-1 analog for the treatment of type 2 diabetes. 64th Annu Meet Sci Sess Am Diabetes Assoc (June 4-8, Orlando) 2004, Abst 634-P.
28. Guivarc'h, P.-H., Castaigne, J.-P., Gagnon, C., Peslherbe, L., Dreyfus, J.H., Drucker, D.J. CJC-1131, a long acting GLP-1 analog safely normalizes post-prandial glucose excursion and fasting glycemia in type 2 diabetes mellitus. 64th Annu Meet Sci Sess Am Diabetes Assoc (June 4-8, Orlando) 2004, Abst 535-P.
29. Guivarch, P.-H., Dreyfus, J.-F., Mathi, S., Castaigne, J.-P., Drucker, D.J. CJC-1131, a long acting GLP-1 analog for type 2 diabetes mellitus: Clinical development update. 40th Annu Meet Eur Assoc Study Diabetes (Sept 5-9, Munich) 2004, Abst 780.
30. ConjuChem updates progress of DAC:GLP-1 development. DailyDrugNews.com (Daily Essentials) Oct 7, 2004.
31. Update on the effects and safety of DAC:GLP-1 in type 2 diabetes. DailyDrugNews.com (Daily Essentials) April 26, 2005.